Leerink Partners Assumes WAVE Life Sciences (WVE) at Outperform
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Leerink Partners assumes coverage on WAVE Life Sciences (NASDAQ: WVE) with a Outperform rating and a price target of $45.00.
Analyst Paul Matteis commented, "In the context of recent safety setbacks for leading players in the oligonucleotide based therapeutic (OBT) space, we believe WVE's proprietary "stereopure" approach to drug development could enable the generation of less immunogenic and more potent nucleic acid medicines. Currently at a ~$960MM market cap, WVE looks expensive for a preclinical/phase I company but is priced at a steep discount (~20% to ~25%) to peers ALNY (MP) and IONS (MP); meanwhile, WVE anticipates rapid progress with 2 imminent IND filings, at least 3 clinical candidates in 2017, and 6 total filed INDs by the end of next year. We believe the theoretical promise of WVE's approach has been validated by $30MM equity investments from TEVA (OP) and PFE (MP), the latter of whom made an additional $10MM payment to partner up to 5 programs targeting metabolic disease."
Shares of WAVE Life Sciences closed at $36.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Fortive (FTV) at Perform
- Deutsche Bank Raises Price Target on IHS Markit (INFO) to $44; Reiterates Buy
- BMO Capital Downgrades Walt Disney (DIS) to Underperform; Too Early to Own for FY18
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!